Stem cell potential for type 1 diabetes therapy

2007 ◽  
Vol 2 (4) ◽  
pp. 449-480
Author(s):  
Enrique Roche ◽  
Miriam Ramírez ◽  
Carmen Ramírez-Castillejo ◽  
Guadalupe Gómez-Mauricio ◽  
Jesús Usón
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Adult Stem Cells ◽  
Cell Function ◽  
Inner Cell Mass ◽  
Cell Mass ◽  
Embryonic Stem ◽  
High Rate ◽  
Β Cell

AbstractStem cells have been considered as a useful tool in Regenerative Medicine due to two main properties: high rate of self-renewal, and their potential to differentiate into all cell types present in the adult organism. Depending on their origin, these cells can be grouped into embryonic or adult stem cells. Embryonic stem cells are obtained from the inner cell mass of blastocyst, which appears during embryonic day 6 of human development. Adult stem cells are present within various tissues of the organism and are responsible for their turnover and repair. In this sense, these cells open new therapeutic possibilities to treat degenerative diseases such as type 1 diabetes. This pathology is caused by the autoimmune destruction of pancreatic β-cells, resulting in the lack of insulin production. Insulin injection, however, cannot mimic β-cell function, thus causing the development of important complications. The possibility of obtaining β-cell surrogates from either embryonic or adult stem cells to restore insulin secretion will be discussed in this review.

From fibroblasts and stem cells: implications for cell therapies and somatic cloning

2005 ◽  
Vol 17 (2) ◽  
pp. 125 ◽  
Author(s):  
Wilfried A. Kues ◽  
Joseph W. Carnwath ◽  
Heiner Niemann
Keyword(s):  
Stem Cells ◽  
Adult Stem Cells ◽  
Inner Cell Mass ◽  
Cell Mass ◽  
Embryonic Stem ◽  
Culture Conditions ◽  
Human Embryos ◽  
Somatic Stem Cells ◽  
Primary Fibroblast ◽  
Cell Therapies

Pluripotent embryonic stem cells (ESCs) from the inner cell mass of early murine and human embryos exhibit extensive self-renewal in culture and maintain their ability to differentiate into all cell lineages. These features make ESCs a suitable candidate for cell-replacement therapy. However, the use of early embryos has provoked considerable public debate based on ethical considerations. From this standpoint, stem cells derived from adult tissues are a more easily accepted alternative. Recent results suggest that adult stem cells have a broader range of potency than imagined initially. Although some claims have been called into question by the discovery that fusion between the stem cells and differentiated cells can occur spontaneously, in other cases somatic stem cells have been induced to commit to various lineages by the extra- or intracellular environment. Recent data from our laboratory suggest that changes in culture conditions can expand a subpopulation of cells with a pluripotent phenotype from primary fibroblast cultures. The present paper critically reviews recent data on the potency of somatic stem cells, methods to modify the potency of somatic cells and implications for cell-based therapies.

scholarly journals Stem Cell and Markers

2019 ◽  
Vol 1 (1) ◽  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Embryonic Stem Cells ◽  
Adult Stem Cells ◽  
Inner Cell Mass ◽  
Cell Mass ◽  
Embryonic Stem ◽  
Stem Cell Markers ◽  
Cell Markers ◽  
Wide Range

Stem cells have the ability to go through various cell divisions and also maintain undifferentiated state. Stem cells are Embryonic (Pluripotent) and adult stem cells. Pluripotent stem cells give rise to all tissues such as ectoderm, mesoderm and endoderm. Embryonic stem cells isolated from inner cell mass of embryo blastocyst. Adult stem cells are also undifferentiated cells present in adult organisms and repair the tissue when damaged occurs but number in less. Adult stem cells are present in bone marrow, adipose tissue, blood and juvenile state umbilical cord and tissue of specific origin like liver, heart, intestine and neural tissue. Embryonic stem cells from blastocyst have the ethical problems and tumorogenecity. These can be identified by flow cytometry. There are wide range of stem cell markers which are useful in identifying them. Most of the pluripotent cell markers are common with tumor cell markers which throws a challenge for certainty.

Can Functionally Mature Islet β-Cells Be Derived from Pluripotent Stem Cells? – A Step Towards Ready-To-Use β-Cells in Type 1 Diabetes

2020 ◽  
Vol 15 ◽  
Author(s):  
Bishnu K Khand ◽  
Ramesh R Bhonde
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Pluripotent Stem Cells ◽  
Cell Function ◽  
Β Cells ◽  
Β Cell ◽  
Β Cell Function ◽  
Glucose Stimulated Insulin Secretion

: Pluripotent Stem Cells [PSCs] are emerging as an excellent cellular source for treatment of many degenerative diseases such as diabetes, ischemic heart failure, Alzheimer’s disease. PSC-derived pancreatic islet β-cells appear to be as a promising therapy for type 1 diabetes patients with impaired β-cell function. Several protocols have been developed to derive β-cells from PSCs. However, these protocols produce β-like cells that show low glucose stimulated insulin secretion [GSIS] function and mirror GSIS profile of functionally immature neonatal β-cells. Several studies have documented a positive correlation between the sirtuins [a family of ageing-related proteins] and the GSIS function of adult β-cells. We are of the view that GSIS function of PSC-derived β-like cells could be enhanced by improving the function of sirtuins in them. Studying the sirtuin expression and activation pattern during the β-cell development and inclusion of the sirtuin activator and inhibitor cocktail [specific to a developmental stage] in the present protocols may help us derive functionally mature, ready-to-use β-cells in-vitro making them suitable for transplantation in type 1 diabetes.

scholarly journals Immune interventions to preserve β cell function in type 1 diabetes

2016 ◽  
Vol 64 (1) ◽  
pp. 7-13 ◽  
Author(s):  
Mario R Ehlers
Keyword(s):  
T Cells ◽  
Type 1 Diabetes ◽  
Regulatory T Cells ◽  
Immune Modulation ◽  
Cell Function ◽  
Cell Mass ◽  
Β Cells ◽  
Β Cell

Type 1 diabetes (T1D) is a chronic autoimmune disease that leads to destruction of pancreatic β cells, lifelong dependence on insulin, and increased morbidity and mortality from diabetes-related complications. Preservation of residual β cells at diagnosis is a major goal because higher levels of endogenous insulin secretion are associated with better short- and long-term outcomes. For the past 3 decades, a variety of immune interventions have been evaluated in the setting of new-onset T1D, including nonspecific immunosuppression, pathway-specific immune modulation, antigen-specific therapies, and cellular therapies. To date, no single intervention has produced durable remission off therapy in most treated patients, but the field has gained valuable insights into disease mechanisms and potential immunologic correlates of success. In particular, T-cell–directed therapies, including therapies that lead to partial depletion or modulation of effector T cells and preservation or augmentation of regulatory T cells, have shown the most success and will likely form the backbone of future approaches. The next phase will see evaluation of rational combinations, comprising one or more of the following: an effector T-depleting or -modulating drug, a cytokine-based tolerogenic (regulatory T-cells–promoting) agent, and an antigen-specific component. The long term goal is to reestablish immunologic tolerance to β cells, thereby preserving residual β cells early after diagnosis or enabling restoration of β-cell mass from autologous stem cells or induced neogenesis in patients with established T1D.

Rapid Point-of-Care Test for Determination of C-Peptide Levels

2021 ◽  
pp. 193229682199555
Author(s):  
Paturi V. Rao ◽  
Eric Bean ◽  
Dhanalakshmi Nair-Schaef ◽  
Siting Chen ◽  
Steven C. Kazmierczak ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Late Onset ◽  
Autoimmune Diabetes ◽  
Point Of Care ◽  
Cell Mass ◽  
Hepatic Clearance ◽  
Β Cell ◽  
C Peptide

C-peptide is co-secreted with insulin and is not subject to hepatic clearance and thus reflects functional β-cell mass. Assessment of C-peptide levels can identify individuals at risk for or with type 1 diabetes with residual β-cell function in whom β cell-sparing interventions can be evaluated, and can aid in distinguishing type 2 diabetes from Latent Autoimmune Diabetes in Adults and late-onset type 1 diabetes. To facilitate C-peptide testing, we describe a quantitative point-of-care C-peptide test. C-peptide levels as low as 0.2 ng/ml were measurable in a fingerstick sample, and the test was accurate over a range of 0.17 to 12.0 ng/ml. This test exhibited a correlation of r = 0.98 with a high-sensitivity commercial ELISA assay and a correlation of r = 0.90 between matched serum and fingerstick samples.

scholarly journals Stem cell properties, current legal status and medical application

2017 ◽  
Vol 71 (0) ◽  
pp. 0-0 ◽  
Author(s):  
Ilona Szabłowska-Gadomska ◽  
Leonora Bużańska ◽  
Maciej Małecki
Keyword(s):  
Stem Cells ◽  
Adult Stem Cells ◽  
Legal Status ◽  
Inner Cell Mass ◽  
Cell Mass ◽  
Embryonic Stem ◽  
Medical Application ◽  
Differentiation Potential ◽  
Differentiated Cells ◽  
Induced Pluripotent

Stem cells due to their unique properties of self-renewal and differentiation play a potential role in the process of damaged tissue repair. Isolated from the inner cell mass of the blastocyst have pluripotential properties and are called embryonic stem cells (ESC). Pluripotential stem cells can be also generated from the differentiated cells by the process of reprogramming and are called induced pluripotent stem cells (iPSC). Stem cells isolated from tissues (somatic or adult stem cells) are more restricted in their differentiation potential and referred as multipotent. The rapid rise in number of clinical trials using somatic stem cells is due to their proved in basic and preclinical studies therapeutic safety and paracrine properties to modulate microenvironment. Increased translation to the clinic of studies using adult stem cells provide hope for patients with diseases for which traditional medicine is powerless .or ineffective. On the other hand progress in iPSC technology allows to derive disease models and personalize future clinical diagnosis and treatment. This paper will focus on characteristics of stem cells, potential application in regenerative medicine, and the current legal status of cell therapy.

scholarly journals β-Cell Replacement in Mice Using Human Type 1 Diabetes Nuclear Transfer Embryonic Stem Cells

Diabetes ◽  
2017 ◽  
Vol 67 (1) ◽  
pp. 26-35 ◽  
Author(s):  
Lina Sui ◽  
Nichole Danzl ◽  
Sean R. Campbell ◽  
Ryan Viola ◽  
Damian Williams ◽  
...  
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Embryonic Stem Cells ◽  
Nuclear Transfer ◽  
Embryonic Stem ◽  
Β Cell ◽  
Cell Replacement ◽  
Human Type ◽  
Human Type 1 Diabetes

scholarly journals Differentiation of Human Embryonic Stem Cells into Neuron, Cholinergic, and Glial Cells

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Kimia Hosseini ◽  
Emilia Lekholm ◽  
Aikeremu Ahemaiti ◽  
Robert Fredriksson
Keyword(s):  
Stem Cells ◽  
Embryonic Stem Cells ◽  
Glial Cells ◽  
Human Embryonic Stem Cells ◽  
Inner Cell Mass ◽  
Cell Mass ◽  
Embryonic Stem ◽  
Cholinergic Neurons ◽  
Neuronal Cultures ◽  
Short Period

Human embryonic stem cells (hESCs) are pluripotent cells, capable of differentiation into different cellular lineages given the opportunity. Derived from the inner cell mass of blastocysts in early embryonic development, the cell self-renewal ability makes them a great tool for regenerative medicine, and there are different protocols available for maintaining hESCs in their undifferentiated state. In addition, protocols for differentiation into functional human neural stem cells (hNSCs), which have the potential for further differentiation into various neural cell types, are available. However, many protocols are time-consuming and complex and do not always fit for purpose. In this study, we carefully combined, optimized, and developed protocols for differentiation of hESCs into adherent monolayer hNSCs over a short period of time, with the possibility of both expansion and freezing. Moreover, the method details further differentiation into neurons, cholinergic neurons, and glial cells in a simple, single step by step protocol. We performed immunocytochemistry, qPCR, and electrophysiology to examine the expression profile and characteristics of the cells to verify cell lineage. Using presented protocols, the creation of neuronal cultures, cholinergic neurons, and a mixed culture of astrocytes and oligodendrocytes can be completed within a three-week time period.

Association of T-cell reactivity with β-cell function in recent onset type 1 diabetes patients

2010 ◽  
Vol 34 (2) ◽  
pp. 127-135 ◽  
Author(s):  
Christian Pfleger ◽  
Guido Meierhoff ◽  
Hubert Kolb ◽  
Nanette C. Schloot
Keyword(s):  
Type 1 Diabetes ◽  
T Cell ◽  
Cell Function ◽  
Β Cell ◽  
Cell Reactivity ◽  
Recent Onset ◽  
Onset Type ◽  
Β Cell Function ◽  
T Cell Reactivity
Sign in / Sign up

Export Citation Format

Share Document